T1	Condition 485 492	disease
T2	Condition-Name 485 492	disease
E1	Condition:T1 Name:T2
T3	Condition 533 540	disease
T4	Condition-Name 533 540	disease
E3	Condition:T3 Name:T4
T5	Condition 594 600	lesion
T6	Condition-Name 594 600	lesion
E5	Condition:T5 Name:T6 Minimum-Count:E39
T9	Procedure 1348 1363	transplantation
T10	Procedure-Name 1348 1363	transplantation
E9	Procedure:T9 Name:T10
T11	Condition 638 657	disease progression
T12	Condition-Name 638 657	disease progression
E11	Condition:T11 Name:T12
T15	Procedure 1042 1054	radiotherapy
T16	Procedure-Name 1042 1054	radiotherapy
E15	Procedure:T15 Name:T16
T18	Eq-Operator 1167 1169	<=
A2	Eq-Operator-Value T18 LTEQ
T19	Eq-Operator 1508 1510	<=
A3	Eq-Operator-Value T19 LTEQ
T20	Eq-Temporal-Unit 990 995	weeks
A4	Eq-Temporal-Unit-Value T20 week
T21	Eq-Temporal-Unit 1513 1519	months
A5	Eq-Temporal-Unit-Value T21 month
T28	Eq-Value 988 989	2
T29	Eq-Value 1171 1172	1
T30	Eq-Comparison 1461 1467	active
E16	Eq-Comparison:T30 Temporal-Period:T31
T31	Eq-Temporal-Period 1461 1467	active
A6	Eq-Temporal-Period-Value T31 present
T32	Eq-Comparison 661 666	prior
E17	Eq-Comparison:T32 Temporal-Period:T33
T33	Eq-Temporal-Period 661 666	prior
A7	Eq-Temporal-Period-Value T33 past
T34	Eq-Comparison 1004 1009	prior
E18	Eq-Comparison:T34 Temporal-Period:T35
T35	Eq-Temporal-Period 1004 1009	prior
A8	Eq-Temporal-Period-Value T35 past
T36	Eq-Comparison 1190 1195	Prior
E19	Eq-Comparison:T36 Temporal-Period:T37
T37	Eq-Temporal-Period 1190 1195	Prior
A9	Eq-Temporal-Period-Value T37 past
T38	Eq-Comparison 1508 1519	<=12 months
E20	Eq-Comparison:T38 Operator:T19 Value:T39 Temporal-Unit:T21
T22	Condition 85 91	cancer
E2	Condition:T22 Name:T40
T40	Condition-Name 85 91	cancer
T41	Modifier 44 84	Metastatic castration-resistant prostate
E4	Modifier:T41 Modifies:T40
T42	Condition 93 98	mCRPC
E6	Condition:T42 Name:T43
T43	Condition-Name 93 98	mCRPC
R1	Abbrev-Of Arg1:E6 Arg2:E2	
T44	Condition 132 146	adenocarcinoma
E8	Condition:T44 Name:T45
T45	Condition-Name 132 146	adenocarcinoma
T46	Procedure 105 115	histologic
E10	Procedure:T46 Name:T47
T47	Procedure-Name 105 115	histologic
R2	Found-By Arg1:E8 Arg2:E10	
T48	And 100 104	with
E12	And:T48 Arg:E6 Arg2:E10
T49	Condition 148 162	Adenocarcinoma
E14	Condition:T49 Name:T50
T50	Condition-Name 148 162	Adenocarcinoma
T51	Modifier 168 178	small-cell
E21	Modifier:T51 Modifies:T50
T52	Modifier 182 196	neuroendocrine
E22	Modifier:T52 Modifies:T50
T53	Or 179 181	or
E23	Or:T53 Arg:E21 Arg2:E22
T54	Condition 218 223	mCRPC
E24	Condition:T54 Name:T55
T55	Condition-Name 218 223	mCRPC
T23	Condition 295 300	mCRPC
E25	Condition:T23 Name:T56
T56	Condition-Name 295 300	mCRPC
T57	Condition 368 377	carcinoma
E26	Condition:T57 Name:T58
T58	Condition-Name 368 377	carcinoma
T59	Modifier 346 367	metastatic renal cell
E27	Modifier:T59 Modifies:T58
T60	Procedure 321 335	pathologically
E28	Procedure:T60 Name:T61
T61	Procedure-Name 321 335	pathologically
R3	Found-By Arg1:E26 Arg2:E28	
T62	Or 318 320	or
E29	Or:T62 Arg:E25 Arg2:E26
T63	Condition 379 382	RCC
E30	Condition:T63 Name:T64
T64	Condition-Name 379 382	RCC
R4	Abbrev-Of Arg1:E30 Arg2:E26	
T24	Modifier 475 484	evaluable
E31	Modifier:T24 Modifies:T2
T65	Modifier 461 471	Measurable
E32	Modifier:T65 Modifies:T2
T66	Or 472 474	or
E33	Or:T66 Arg:E32 Arg2:E31
T25	Modifier 523 532	evaluable
E34	Modifier:T25 Modifies:T4
T67	Modifier 509 519	measurable
E35	Modifier:T67 Modifies:T4
T68	Or 520 522	or
E36	Or:T68 Arg:E35 Arg2:E34
T69	Condition 554 560	cancer
E37	Condition:T69 Name:T70
T70	Condition-Name 554 560	cancer
T71	Modifier 545 553	prostate
E38	Modifier:T71 Modifies:T70
R5	Example-Of Arg1:E37 Arg2:E3	
T26	Eq-Comparison 570 582	At least one
E39	Eq-Comparison:T26 Operator:T72 Value:T73
T72	Eq-Operator 570 578	At least
A11	Eq-Operator-Value T72 GTEQ
T73	Eq-Value 579 582	one
T7	Procedure 667 674	therapy
E7	Procedure:T7 Name:T8 Temporality:E17
T8	Procedure-Name 667 674	therapy
T74	Procedure 703 712	treatment
E40	Procedure:T74 
R6	Found-By Arg1:E11 Arg2:E7	
R7	Treatment-For Arg1:E40 Arg2:E11	
T75	Assertion 680 688	requires
E41	Assertion:T75 Asserted:E40
A12	Assertion-Type-Value E41 hypothetical
T27	Condition 747 754	lesions
E42	Condition:T27 Name:T76
T76	Condition-Name 747 754	lesions
T77	Procedure 889 897	biopsies
E43	Procedure:T77 Name:T78
T78	Procedure-Name 889 897	biopsies
T79	Modifier 877 888	fresh tumor
E44	Modifier:T79 Modifies:T78
T80	Assertion 846 854	agree to
E45	Assertion:T80 Asserted:E43
A13	Assertion-Type-Value E45 hypothetical
T81	Procedure 924 930	biopsy
E46	Procedure:T81 Name:T82
T82	Procedure-Name 924 930	biopsy
T83	Risk 949 953	risk
E47	Risk:T83 
R8	Caused-By Arg1:E47 Arg2:E46	
T84	Exception 899 905	unless
E48	Exception:T84 From:E43 Except:E46
T85	Eq-Comparison 979 995	At least 2 weeks
E49	Eq-Comparison:T85 Operator:T86 Temporal-Unit:T20 Value:T28
T86	Eq-Operator 979 987	At least
A14	Eq-Operator-Value T86 GTEQ
T87	Procedure 1010 1030	anticancer treatment
E50	Procedure:T87 Name:T88 Temporality:E18
T88	Procedure-Name 1010 1030	anticancer treatment
R9	Example-Of Arg1:E15 Arg2:E50	
T89	Study 1094 1099	study
E51	Study:T89 Study-Of:E52
T90	Drug 1100 1104	drug
E52	Drug:T90 Name:T91 Temporality:E53 Temporality2:E49
T91	Drug-Name 1100 1104	drug
T92	Eq-Comparison 1080 1085	first
E53	Eq-Comparison:T92 Temporal-Recency:T93
T93	Eq-Temporal-Recency 1080 1085	first
A15	Eq-Temporal-Recency-Value T93 first-time
T94	Temporal-Connection 996 1003	between
E54	Temporal-Connection:T94 Arg:E50 Arg2:E49
A16	Temporal-Connection-Type-Value E54 after
T17	Observation 1110 1120	toxicities
E55	Observation:T17 Name:T95 Eq-Comparison:E56
T95	Observation-Name 1110 1120	toxicities
T96	Eq-Comparison 1138 1172	Grade less than or equal to (<=) 1
E56	Eq-Comparison:T96 Unit:T97 Operator:T98 Operator2:T18 Value:T29
T97	Eq-Unit 1138 1143	Grade
T98	Eq-Operator 1144 1162	less than or equal
A1	Eq-Operator-Value T98 LTEQ
T99	Study 1176 1184	baseline
E57	Study:T99 
T100	Or 1173 1175	or
E58	Or:T100 Arg:E56 Arg2:E57
T101	Procedure 1196 1205	treatment
E59	Procedure:T101 Temporality:E19
T102	Drug 1211 1245	prostate-specific membrane antigen
E60	Drug:T102 Name:T103
T103	Drug-Name 1211 1245	prostate-specific membrane antigen
T104	Drug 1247 1251	PSMA
E61	Drug:T104 Name:T105
T105	Drug-Name 1247 1251	PSMA
R10	Using Arg1:E59 Arg2:E60	
R11	Abbrev-Of Arg1:E61 Arg2:E60	
T13	Immunization 1281 1302	PSMA-targeted vaccine
E13	Immunization:T13 Name:T14
T14	Immunization-Name 1281 1302	PSMA-targeted vaccine
T106	Exception 1270 1276	except
E62	Exception:T106 From:E61 Except:E13
T107	Modifier 1336 1347	bone marrow
E63	Modifier:T107 Modifies:T10
T108	Modifier 1321 1332	Solid organ
E64	Modifier:T108 Modifies:T10
T109	Or 1333 1335	or
E65	Or:T109 Arg:E64 Arg2:E63
T110	Condition 1386 1395	condition
E66	Condition:T110 
T111	Condition 1369 1376	Seizure
E67	Condition:T111 Name:T112
T112	Condition-Name 1369 1376	Seizure
T113	Or 1377 1379	or
E68	Or:T113 Arg:E67 Arg2:E66
T114	Condition 1419 1426	seizure
E69	Condition:T114 Name:T115
T115	Condition-Name 1419 1426	seizure
T116	Condition 1430 1449	intracranial masses
E70	Condition:T116 Name:T117
T117	Condition-Name 1430 1449	intracranial masses
T118	Or 1427 1429	or
E71	Or:T118 Arg:E69 Arg2:E70
T119	Assertion 1401 1404	may
E72	Assertion:T119 Asserted:E69 Asserted2:E70
A17	Assertion-Type-Value E72 hypothetical
R12	Caused-By Arg1:E69 Arg2:E66	
T120	Condition 1468 1478	malignancy
E73	Condition:T120 Name:T121 Temporality:E16
T121	Condition-Name 1468 1478	malignancy
T122	Other 1455 1460	Other
E74	Other:T122 Is-Other:E73
T123	Procedure 1498 1507	treatment
E75	Procedure:T123 Temporality:E20
T124	Modifier 1489 1497	systemic
E76	Modifier:T124 Modifies:E75
T125	Assertion 1479 1488	requiring
E77	Assertion:T125 Asserted:E75
A18	Assertion-Type-Value E77 hypothetical
R13	Treatment-For Arg1:E75 Arg2:E73	
T39	Eq-Value 1510 1512	12
T126	Study 1529 1539	enrollment
E78	Study:T126 
T127	Temporal-Connection 1520 1528	prior to
E79	Temporal-Connection:T127 Arg:E20 Arg2:E78
A10	Temporal-Connection-Type-Value E79 before
